

Recombinant Human BCHE

Accombinant Human DCHE	
Catalog#:P01887 Derived from Human Cells	
DESCRIPTION	Recombinant Human Butyrylcholine Esterase is produced by our Mammalian expression system and the target gene encoding Glu29- Leu602 is expressed with a 6His tag at the C-terminus. Accession#: P06276 Known as: Cholinesterase; Acylcholine Acylhydrolase; Butyrylcholine Esterase;
	Choline Esterase II; Pseudocholinesterase; BCHE; CHE1
FORMULATION	Supplied as a 0.2µm filtered solution of 20mM Tris- HCl, 150mM NaCl, pH 7.5.
SHIPPING	The product is shipped on dry ice/polar packs. Upon receipt, store it immediately at the temperature listed below.
STORAGE	Store at \leq -70°C, stable for 6 months after receipt. Store at \leq -70°C, stable for 3 months under sterile conditions after opening. Please minimize freeze-thaw cycles.
QUALITY	Mol Mass:66.12kDaAP Mol Mass:90kDa, reducing conditions.Purity: Greater than 95% as determined by reducing SDS-PAGE.
CONTROL	Endotoxin : Less than 0.1 ng/ μ g (1 EU/ μ g) as determined by LAL test.
BACKGROUND	Butyrylcholine Esterase (BCHE) is a secreted protein that belongs to the type-B carboxylesterase/lipase family. BCHE is a major acetylcholine hydrolyzing enzyme in the circulation. It is detected in blood plasma and present in most cells except erythrocytes. BCHE is an esterase with broad substrate specificity. BCHE can contribute to the inactivation of the neurotransmitter acetylcholine. BCHE can degrade a large number of neurotoxic organophosphate esters. Thus, it plays important pharmacological and toxicological roles and is thought to be involved in the pathological progression. Defects in BCHE are the cause of butyrylcholinesterase deficiency (BChE deficiency) which is a metabolic disorder characterized by prolonged apnoea after the use of certain anesthetic drugs, including the muscle relaxants succinylcholine and other ester local anesthetics.
kDa MK R 120 90 90 90 40 90 40 30 90 20 14 14	